^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | RK-33 (DDX3 inhibitor) |
| Drug Class: | PARP inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer
Excerpt:
...DDX3 expression levels are similar in breast cancers in BRCA1/BRCA2 germline mutation carriers and sporadic breast cancers. BRCA1 pro- and deficient breast cancer cell lines were equally sensitive to RK-33 treatment and therefore show similar DDX3 dependency. Interestingly, DDX3 inhibition with RK-33 synergizes with PARP inhibitor treatment in breast cancer cells, especially in a BRCA1-proficient background.
DOI:
10.1007%2Fs12032-017-0889-2